Caxton Associates LLP Purchases New Shares in Eli Lilly and Company $LLY

Key Points

• Caxton Associates LLP has acquired a new stake in Eli Lilly and Company, purchasing 2,570 shares valued at approximately $2,123,000.
• Several institutional investors, including Redwood Investments and O'Brien Wealth Partners, have adjusted their positions in Eli Lilly, contributing to a collective institutional ownership of 82.53%.
• Eli Lilly recently reported earnings exceeding expectations, with $6.31 per share and revenue of $15.56 billion, driving a year-over-year revenue increase of 37.6%.

Caxton Associates LLP bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,570 shares of the company's stock, valued at approximately $2,123,000.

Other hedge funds have also recently bought and sold shares of the company. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $27,000. Citizens National Bank Trust Department grew its position in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company in the first quarter worth $40,000. Finally, Mascagni Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at $43,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO David A. Ricks acquired 1,632 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jamere Jackson bought 200 shares of the company's stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock valued at $2,894,841 over the last 90 days. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $11.35 during mid-day trading on Tuesday, reaching $749.99. The stock had a trading volume of 2,983,536 shares, compared to its average volume of 4,436,129. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $942.35. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The business's 50 day moving average price is $742.49 and its 200 day moving average price is $779.42. The company has a market cap of $709.84 billion, a P/E ratio of 49.02, a price-to-earnings-growth ratio of 1.03 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the business posted $3.92 earnings per share. The company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio is 39.22%.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Leerink Partners reissued a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. UBS Group dropped their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Morgan Stanley reissued an "overweight" rating and set a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Finally, DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.